
Transition Therapeutics has bought Lilly’s early-stage osteoarthritis drug TT-601 that is designed to help patients with chronic bone pain. Transition …

Eli Lilly is to take up its option to develop and commercialise a type 2 diabetes candidate, paying Canadian firm …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

